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Osteoporosis disease is a metabolic disor-
der in which bone mineral density (BMD)
is lower than the normal threshold. Based
on literature, it is known that schizophrenic
patients due to consuming anti-psychotic
drugs and Parkinson’s disease patients due
to vitamin D deficiency and decrease in
mobility are at the high risk of osteoporosis
(1–4).
On the other hand, it is observed that
adenosine 5′-monophosphate (AMP)-
activated protein kinase (AMPK) activity,
which is regulating cellular energy home-
ostasis, is reduced in schizophrenia diseases
(5). In addition, it is known that there is
mitochondrial dysfunction in Parkinson’s
disease that can be treated by AMPK, which
is identified as a mitochondrial biogenesis
(6–8). Recently, some findings show that
AMPK plays an important role in bone
metabolism. Besides, some in vitro studies
revealing that AMPK modulators regu-
late bone cell function (9–13). Also, some
studies show that deficiency of AMPK α
and β subunits in mice causes bone loss
in vivo (14).
Based on the above mentioned points,
it can be referred that AMPK deficiency
in Parkinson’s disease and schizophrenia
may lead to osteoporosis. This can be used
as a goal in treatment of osteoporosis in
those disorders. In another word, nowa-
days there are some drugs available for both
diseases but they have some side effect,
which may lead to osteoporosis; by con-
sidering the fact that AMPK deficiency
may cause osteoporosis, new drugs can
be provided with AMPK supplement to
reduce the osteoporosis symptoms. Surely,
experimental trials are needed to validate
our hypothesis.
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